DNA repair gene XRCC3 Thr241Met polymorphism and susceptibility to glioma: A case-control study

Xu, Guohai; Wang, Maode; Xie, Wei; Bai, Xia

doi:10.3892/ol.2014.2192

Cited by 7 publications

(5 citation statements)

References 32 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of recent studies have indicated that gene polymorphism is closely associated with risk of glioma formation. Xu et al (2014) showed that the X-ray repair cross complementing group 3 gene (XRCC3) Thr241Met polymorphism increases glioma susceptibility, as its frequency is significantly higher in glioma patients as compared with the control subjects. Retinoblastoma binding protein 6 gene variants were also reported to be associated with glioma, and contribute to glioma susceptibility (Hu et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

CXCL12 G801A polymorphism and susceptibility to glioma: a case‑control study

Chang

Yang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Previous studies have demonstrated that the CXCL12 G801A polymorphism is closely correlated with tumor susceptibility. In addition, the CXCL12/CXCR4 pathway is closely related to proliferation, metastasis, and invasion of glioma. However, the genetic effects of the CXCL12 G801A polymorphism on glioma risk in Chinese populations remain unknown. In this study, we investigated the potential associations between the CXCL12 G801A polymorphism with glioma susceptibility and its clinicopathological characteristics. Frequencies of CXCL12 G801A polymorphic variants between glioma patients (N = 750) and healthy controls (N = 750) were assessed using restriction length fragment polymorphism analysis. The association among the CXCL12 G801A polymorphism, glioma grade (WHO classification), and histological type was also evaluated. Our results showed that patients with glioma had significantly higher frequency of the CXCL12-3' A/A genotypes (P = 0.039) as compared with healthy controls. When stratified by the glioma histology, high-grade glioma patients had significantly higher frequency of the CXCL12-3' A/A genotypes (P = 0.019) as compared with low-grade glioma patients. When stratified by the WHO grade, significantly higher frequency of the CXCL12-3' A/A genotype was observed in stage IV glioma patients (P = 0.037). We conclude that the CXCL12 G801A polymorphism is a risk factor that increases susceptibility to gliomas in a subset of the general Han Chinese population.

show abstract

Section: Discussionmentioning

confidence: 99%

CXCL12 G801A polymorphism and susceptibility to glioma: a case‑control study

Chang

Yang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…The final 14 eligible studies included a total of 12,905 study participants, including 5,852 cases and 7,053 controls (Table 1). Eight (8) of these 14 studies were conducted in China, with subjects from the Asian population [28,33,37,39,40,[42][43][44]; the other seven studies were predominantly Caucasian-with three studies from the United States [21,24,36] and one each from Spain [41] and Brazil [34], and one study from multiple countries [18]. In addition, 11 studies used hospital-based controls [21,24,33,36,37,[39][40][41][42][43][44], whereas the remaining 3 studies opted for population-based controls [18,34,36].…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

“…Eight (8) of these 14 studies were conducted in China, with subjects from the Asian population [28,33,37,39,40,[42][43][44]; the other seven studies were predominantly Caucasian-with three studies from the United States [21,24,36] and one each from Spain [41] and Brazil [34], and one study from multiple countries [18]. In addition, 11 studies used hospital-based controls [21,24,33,36,37,[39][40][41][42][43][44], whereas the remaining 3 studies opted for population-based controls [18,34,36]. In addition, all studies except Liu et al [36] reported the frequencies of the three genotypes (Thr/Thr, Thr/Met, and Met/Met) separately.…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

“…For this reason, this polymorphism has been studied in numerous malignancies, including bladder cancer, head and neck cancer, ovarian cancer, and colorectal cancer, and significant associations have been demonstrated in some cases [28][29][30][31][32]. However, in gliomas, the association between this polymorphism and susceptibility to this cancer remains unclear [18,21,24,[33][34][35][36][37][38][39][40][41][42][43][44]. To clarify this, we performed a meta-analysis to further investigate the association between the XRCC3 p.Thr241Met polymorphism and glioma risk.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between XRCC3 p.Thr241Met polymorphism and risk of glioma: A systematic review and meta-analysis

Tan

Low²,

Hussain³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background The XRCC3 p.Thr241Met (rs861539) polymorphism has been extensively studied for its association with glioma risk, but results remain conflicting. Therefore, we performed a systematic review and meta-analysis to resolve this inconsistency. Methods Studies published up to June 10, 2022, were searched in PubMed, Web of Science, Scopus, VIP, Wanfang, and China National Knowledge Infrastructure databases and screened for eligibility. Then, the combined odds ratio (OR) of the included studies was estimated based on five genetic models, i.e., homozygous (Met/Met vs. Thr/Thr), heterozygous (Thr/Met vs. Thr/Thr), dominant (Thr/Met + Met/Met vs. Thr/Thr), recessive (Met/Met vs. Thr/Thr + Thr/Met) and allele (Met vs. Thr). The study protocol was preregistered at PROSPERO (registration number: CRD42021235704). Results Overall, our meta-analysis of 14 eligible studies involving 12,905 subjects showed that the p.Thr241Met polymorphism was significantly associated with increased glioma risk in both homozygous and recessive models (homozygous, OR = 1.381, 95% CI = 1.081–1.764, P = 0.010; recessive, OR = 1.305, 95% CI = 1.140–1.493, P<0.001). Subgroup analyses by ethnicity also revealed a statistically significant association under the two aforementioned genetic models, but only in the Asian population and not in Caucasians (P>0.05). Conclusion We demonstrated that the XRCC3 p.Thr241Met polymorphism is associated with an increased risk of glioma only in the homozygous and recessive models.

show abstract

“…This polymorphism is mentioned as Thr241Met. Several studies have evaluated the association between Thr241Met polymorphisms and GC susceptibility (17,(19)(20)(21). There are controversies and diversities in the effect of Thr241Met polymorphism on GC, especially in Asian countries.…”

Section: Introductionmentioning

confidence: 99%

Genetic Polymorphism of Thr241Met and Other Risk Factors Related with Gastric Cancer in Iranian Military Population: A Pilot Case Control Study

et al. 2019

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is a result of interaction between genetic and environmental factors. The recognition of GC risk factors is very important for early diagnostic and prevention from this cancer. Objectives: The objective of this study was to investigate the effects of some factors such as Thr241Met polymorphism on GC occurrence in Iranian military population. Methods: Investigated samples in the present study were 53 tissue samples from patients with pathologically proven GC and 91 sex-age matched blood samples from healthy controls. Data for cases and controls were obtained through registered files and questionnaires, respectively. Genomic DNA was extracted and PCR-RFLP was used for genotyping of Thr241Met polymorphism. Chi-square and odds ratio (OR) were used to determine the factors affecting the incidence of GC. Results: The Thr\Met genotype of Thr241Met polymorphism of the XRCC3 gene (P = 0.04 and OR = 2.99) and blood type B (P = 0.04 and OR = 2.99) significantly affected the incidence of GC. This study did not prove the significant effect of smoking (P = 0.08 and OR = 2.47) and positive family history (P = 0.13 and OR = 2.25) on GC risk. Conclusions: These findings may be helpful in early identification of high-risk individuals, especially in military population and prevention from GC.

show abstract

DNA repair gene XRCC3 Thr241Met polymorphism and susceptibility to glioma: A case-control study

Cited by 7 publications

References 32 publications

CXCL12 G801A polymorphism and susceptibility to glioma: a case‑control study

CXCL12 G801A polymorphism and susceptibility to glioma: a case‑control study

Association between XRCC3 p.Thr241Met polymorphism and risk of glioma: A systematic review and meta-analysis

Genetic Polymorphism of Thr241Met and Other Risk Factors Related with Gastric Cancer in Iranian Military Population: A Pilot Case Control Study

Contact Info

Product

Resources

About